MedTrace Logo

Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy

NCT02911311 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 226

Last updated 2021-02-25

No results posted yet for this study

Summary

Panretinal photocoagulation (PRP) has been the standard treatment for Proliferative diabetic retinopathy (PDR) since the Diabetic Retinopathy Study demonstrated its benefit nearly 40 years ago,but PRP has inevitable adverse effects on visual function. Intravitreal injection of vascular endothelial growth factor(VEGF) can induce short-term regression of retinal neovascularization(NV). The purpose is to assess and compare the efficacy and safety between intravitreal injection of conbercept and PRP.

Conditions

  • Proliferative Diabetic Retinopathy

Interventions

DRUG

intravitreal injection of conbercept

conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration

DEVICE

PRP

panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Chenjin Jin, Dr. · Zhongshan Ophthalmic Center, Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-12
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02911311 on ClinicalTrials.gov